AL AMYLOIDOSIS
Clinical trials for AL AMYLOIDOSIS explained in plain language.
Never miss a new study
Get alerted when new AL AMYLOIDOSIS trials appear
Sign up with your email to follow new studies for AL AMYLOIDOSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for Tough-to-Treat amyloidosis: 3-Drug combo enters human testing
Disease control OngoingThis early-phase study tests a combination of three drugs (venetoclax, ixazomib, and dexamethasone) in 24 people with a rare blood disease called light chain amyloidosis that has returned or not responded to prior therapy. The goal is to find the best dose and check for side effe…
Matched conditions: AL AMYLOIDOSIS
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 08:12 UTC
-
New Slow-Go drug shows promise for rare blood disease
Disease control OngoingThis early-phase trial tests a drug called isatuximab in 11 people with a rare, high-risk blood disease called AL amyloidosis. The goal is to see if a slower, gentler treatment approach can control the disease with fewer side effects. Isatuximab is an antibody that helps stop abn…
Matched conditions: AL AMYLOIDOSIS
Phase: PHASE1 • Sponsor: Emory University • Aim: Disease control
Last updated May 17, 2026 08:03 UTC
-
New antibody could clear toxic proteins and extend life in rare disease
Disease control OngoingThis study tests an experimental drug called CAEL-101 in people with AL amyloidosis, a rare disease where abnormal proteins build up in organs like the heart and kidneys. The drug is designed to remove these protein deposits. The trial includes 281 participants who have not recei…
Matched conditions: AL AMYLOIDOSIS
Phase: PHASE3 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New maintenance drug aims to delay relapse in rare blood disease
Disease control OngoingThis study tests whether the chemotherapy drug Ixazomib, given as maintenance therapy, can help control AL amyloidosis and prevent or delay the disease from coming back. The trial involves 17 adults who have already received initial treatment. Researchers are measuring how long p…
Matched conditions: AL AMYLOIDOSIS
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New hope for hard-to-treat amyloidosis patients with prior daratumumab exposure
Disease control OngoingThis study tests a combination of three drugs (daratumumab, pomalidomide, and dexamethasone) in 15 adults with AL amyloidosis whose disease has returned or not responded after prior treatment including daratumumab. The goal is to see if this triple therapy leads to more complete …
Matched conditions: AL AMYLOIDOSIS
Phase: PHASE2 • Sponsor: Weill Medical College of Cornell University • Aim: Disease control
Last updated May 13, 2026 16:03 UTC
-
New antibody could extend life for patients with rare, fatal amyloidosis
Disease control OngoingThis study tests an experimental drug called CAEL-101 in people with a rare disease called AL amyloidosis, where abnormal proteins build up in organs like the heart and kidneys. The drug aims to remove these protein deposits to help patients live longer and avoid heart-related ho…
Matched conditions: AL AMYLOIDOSIS
Phase: PHASE3 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 11, 2026 20:40 UTC
-
New drug aims to ease tough recovery after stem cell transplant for older cancer patients
Symptom relief OngoingThis study tests whether giving siltuximab before and after an autologous stem cell transplant can reduce symptoms like fatigue, pain, and nausea in patients aged 60 to 75 with multiple myeloma or AL amyloidosis. The drug blocks a protein called IL-6 that is linked to inflammatio…
Matched conditions: AL AMYLOIDOSIS
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief
Last updated May 17, 2026 08:02 UTC